References
- Kim JJ, Hong YM, Yun SW, Han MK, Lee KY, Song MS, et al. Assessment of risk factors for Korean children with Kawasaki disease. Pediatr Cardiol 2012;33:513-20. https://doi.org/10.1007/s00246-011-0143-1
- Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. https://doi.org/10.1542/peds.2004-2182
- Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6:535-42. https://doi.org/10.1016/j.intimp.2005.11.015
- Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55. https://doi.org/10.1056/NEJMra993360
- Sakata K, Hamaoka K, Ozawa S, Niboshi A, Yoshihara T, Nishiki T, et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr 2007;166: 565-71. https://doi.org/10.1007/s00431-006-0280-3
- Yeo JS, Choi JW. Effectiveness of medium-dose intravenous immunoglobulin (1 g/kg) in the treatment of Kawasaki disease. Korean Circ J 2010;40:81-5. https://doi.org/10.4070/kcj.2010.40.2.81
- JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J 2014;78:2521-62. https://doi.org/10.1253/circj.CJ-66-0096
- Japan Kawasaki Disease Research Committee. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo: Ministry of Health and Welfare, 1984.
- Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013;27:171-8. https://doi.org/10.1016/j.tmrv.2013.05.004
- Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283-98. https://doi.org/10.1016/S0001-2998(78)80014-2
- Cantor SB, Sun CC, Tortolero-Luna G, Richards-Kortum R, Follen M. A comparison of C/B ratios from studies using receiver operating characteristic curve analysis. J Clin Epidemiol 1999;52:885-92. https://doi.org/10.1016/S0895-4356(99)00075-X
- Onouchi Z, Kawasaki T. Overview of pharmacological treatment of Kawasaki disease. Drugs 1999;58:813-22. https://doi.org/10.2165/00003495-199958050-00004
- Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatr Int 1999;41:1-7. https://doi.org/10.1046/j.1442-200X.1999.t01-1-01014.x
- Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9. https://doi.org/10.1056/NEJM199106063242305
- Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001;62:133-7. https://doi.org/10.1159/000056085
- Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
- Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
- Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
- de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998;133:254-8. https://doi.org/10.1016/S0022-3476(98)70229-X
Cited by
- Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease vol.70, pp.None, 2020, https://doi.org/10.1016/j.phymed.2020.153208
- Predictive value of C-reactive protein to albumin ratio as a biomarker for initial and repeated intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients: a prospective coho vol.19, pp.1, 2016, https://doi.org/10.1186/s12969-021-00517-1
- Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study vol.19, pp.1, 2016, https://doi.org/10.1186/s12969-021-00638-7